Expression of Stathmin in Localized Upper Urinary Tract Urothelial Carcinoma: Correlations With Prognosis

Urology

Volumn 74, Issue 6, 2009, Pages 1264-1269

  Lin, Wei Chou ^a   Chen, Shyh Chyan ^a   Hu, Fu Chang ^a   Chueh, Shih Chieh ^a   Pu, Yeong Shiau ^a   Yu, Hong Jeng ^a   Huang, Kuo How ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; STATHMIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; URINARY TRACT CARCINOMA; UROGENITAL TRACT TUMOR; UROTHELIUM;

AGED; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, MESSENGER; STATHMIN; URETERAL NEOPLASMS;

EID: 70749116365     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.04.088     Document Type: Article

References (26)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin. 58 (2008) 71-96
2. Muntener M., Nielsen M.E., Romero F.R., et al. Long-term oncologic outcome after laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma. Eur Urol. 51 (2007) 1639-1644
3. Oosterlinck W. Ureteral tumour: a specific upper urinary tract transitional cell carcinoma. Eur Urol. 51 (2007) 1164-1165
4. Hall M.C., Womack S., Sagalowsky A.I., et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52 (1998) 594-601
5. Novara G., De Marco V., Gottardo F., et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer 110 (2007) 1715-1722
6. Olgac S., Mazumdar M., Dalbagni G., et al. Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol. 28 (2004) 1545-1552
7. Lin W.C., Hu F.C., Chung S.D., et al. The role of lymphovascular invasion in predicting the prognosis of clinically localized upper tract urothelial carcinoma (pT1-3cN0M0). J Urol. 180 (2008) 879-884
8. Park S., Hong B., Kim C.S., et al. The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol. 171 2 Pt. 1 (2004) 621-625
9. Saito K., Kawakami S., Fujii Y., et al. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically. J Urol. 178 (2007) 2291-2296
10. Fromont G., Roupret M., Amira N., et al. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol. 48 (2005) 764-770
11. Langner C., Rupar G., Leibl S., et al. Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch. 448 (2006) 325-330
12. Leibl S., Zigeuner R., Hutterer G., et al. EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS 116 (2008) 27-32
13. Ferrari A.C., Seuanez H.N., Hanash S.M., et al. A gene that encodes for a leukemia-associated phosphoprotein (p18) maps to chromosome bands 1p35-36.1. Genes Chromosomes Cancer 2 (1990) 125-129
14. Rubin C.I., and Atweh G.F. The role of stathmin in the regulation of the cell cycle. J Cell Biochem. 93 (2004) 242-250
15. Cassimeris L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol. 14 (2002) 18-24
16. Yuan R.H., Jeng Y.M., Chen H.L., et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 209 (2006) 549-558
17. Chen G., Wang H., Gharib T.G., et al. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2 (2003) 107-116
18. Kouzu Y., Uzawa K., Koike H., et al. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 94 (2006) 717-723
19. Saal L.H., Johansson P., Holm K., et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 104 (2007) 7564-7569
20. Ghosh R., Gu G., Tillman E., et al. Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate 67 (2007) 1038-1052
21. Wei S.H., Lin F., Wang X., et al. Prognostic significance of stathmin expression in correlation with metastasis and clinicopathological characteristics in human ovarian carcinoma. Acta Histochem. 110 (2008) 59-65
22. Hsu H.C., Jeng Y.M., Mao T.L., et al. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 157 (2000) 763-770
23. Nishio K., Nakamura T., Koh Y., et al. Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells. Cancer 91 (2001) 1494-1499
24. Mistry S.J., Bank A., and Atweh G.F. Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure. Mol Cancer Res. 5 (2007) 773-782
25. Iancu C., Mistry S.J., Arkin S., et al. Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle. Cancer Res. 60 (2000) 3537-3541
26. Gallagher D.J., Milowsky M.I., and Bajorin D.F. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer 113 (2008) 1284-1293